title: The management of acute myelogenous leukemia.
abstract: Although definite improvement in the treatment of acute myelogenous leukemia has taken place, the outlook  for patients remains grim. The current aggressive approach to treatment, entailing a program of chemotherapy which almost invariably produces bone marrow aplasia and considerable toxicity, has been the subject of some controversy. Selected aspects of management are discussed.
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001803:Blood Transfusion; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D017053:Infection Control; D007700:Kinetics; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009181:Mycoses / Q000150:complications; D011241:Prednisone / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000150:complications; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate